眾生藥業(002317.SZ):控股子公司眾生睿創穫得日本專利證書
格隆匯11月18日丨眾生藥業(002317.SZ)公佈,公司控股子公司眾生睿創收到日本特許廳頒發的專利證書。具體情況如下:專利名稱:チロシンキナーゼ阻害剤およびそれを含む醫薬組成物(酪氨酸激酶抑制劑及包含該酪氨酸激酶抑制劑的藥物組合物)。
該專利是眾生睿創開發的具有治療特發性肺纖維化(IPF)和惡性腫瘤雙重作用的一類創新藥ZSP1603項目的化合物專利,屬於該項目的核心專利。ZSP1603是國內同靶點首個獲批臨牀用於治療IPF的小分子創新藥物。
目前,ZSP1603膠囊正在特發性肺纖維化患者中進行Ib/IIa期臨牀研究,首例受試者已經入組,相關工作正按計劃積極推進中。截至目前,ZSP1603項目化合物核心專利已經獲得日本、美國、中國的專利授權,此次項目化合物獲得專利授權有利於公司進一步完善知識產權保護體系,發揮自主知識產權優勢,保持技術領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.